Health News Stories

Excerpts of Key Health News Stories in Major Media

Below are key excerpts of revealing news articles on health from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

For further exploration, delve into our comprehensive Health and Food Corruption Information Center.

Note: This comprehensive list of news stories is usually updated once a week. Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.

Dr. Julie Gerberding, former director of the U.S. Centers for Disease Control and Prevention, was named president of Merck & Co Inc's vaccine division. Gerberding, who led the CDC from 2002 to 2009 and stepped down when President Barack Obama took office, will head up the company's $5 billion global vaccine business that includes shots to prevent chickenpox, cervical cancer and pneumonia. She had led CDC from one crisis to another, including the investigation into the anthrax attacks that killed five people in 2001, the H5N1 avian influenza, the global outbreak of severe acute respiratory syndrome, or SARS, and various outbreaks of food poisoning. She may be charged with reigniting flagging sales of Merck's Gardasil vaccine to prevent cervical cancer by protecting against human papillomavirus or HPV. After an encouraging launch Gardasil sales have been falling and were down 22 percent in the third quarter at $311 million.

Note: So the head of the CDC now is in charge of vaccines at one of the biggest pharmaceutical companies in the world. Could this be considered conflict of interest? Could this possibly be payback for supporting the vaccine agenda so strongly for years? For more on the risks and dangers of vaccines, click here.

A healthcare firm is seeking to silence a Danish academic from expressing doubts about one of its products by using England’s draconian libel laws. Two years ago in a conference room in the Randolph hotel in Oxford, Henrik Thomsen ... one of Europe’s leading radiologists, revealed how patients treated at his hospital had subsequently contracted a rare and potentially fatal disease. Thomsen and other doctors at his Copenhagen University hospital were baffled as to why 20 kidney patients who had been given routine scans were afflicted by a disorder — nephrogenic systemic fibrosis (NSF) — in which the skin gradually swells, thickens and tightens. Some sufferers were confined to wheelchairs. At least one died. There was no known cure. It was confirmed that all those who had fallen ill with NSF had been given the same drug in advance of a magnetic resonance imaging (MRI) scan. Omniscan was used to enhance the images produced by the scan. The product was sold around the world and was manufactured by GE Healthcare, a subsidiary of General Electric, one of the world’s largest corporations. Thomsen ... now refuses to speak anywhere in England on the possible risks of Omniscan. The reason is that he faces another kind of storm: GE Healthcare is suing him in the High Court for libel. GE has already racked up costs of more than Ł380,000 pursuing the respected academic. Thomsen will have to pay the firm’s costs if he loses the case.

Note: For lots more on corporate corruption from reliable sources, click here.

[Bill Moyers:] Something's not right here. One year after the great collapse of our financial system, Wall Street is back on top while our politicians dither. As for health care reform, you're about to be forced to buy insurance from companies whose stock is soaring, and that's just dandy with the White House. It's capital. Raw money, mounds of it, buying politicians and policy as if they were futures on the hog market. Some of the big insurance companies, Well Point, Cigna, United Health, all surged to a 52 week high in their share prices this week when it was clear there'd be no public option in the health care bill going through Congress right now. What does that tell you? ROBERT KUTTNER: Their strategy was cut a deal with the insurance companies, the drug industry going in. And the deal was, we're not going to attack your customer base, we're going to subsidize a new customer base. And that script was pre-cooked so it's not surprising that this is what comes out the other side. Once the White House made this deal with the insurance companies, the public option was never going to be anything more than a fig leaf. And over the summer and the fall, it got whittled down, whittled down, whittled down to almost nothing and now it's really nothing.

Note: For lots more on corporate and government corruption from reliable sources, click here and here.

Deep inside an 86-page supplement to United States export regulations is a single sentence that bars U.S. exports of vaccines for avian bird flu and dozens of other viruses to five countries designated "state sponsors of terrorism." The reason: Fear that they will be used for biological warfare. Under this little-known policy, North Korea, Iran, Cuba, Syria and Sudan may not get the vaccines unless they apply for special export licenses, which would be given or refused according to the discretion and timing of the U.S. Three of those nations -- Iran, Cuba and Sudan -- also are subject to a ban on all human pandemic influenza vaccines as part of a general U.S. embargo. The regulations, which cover vaccines for everything from Dengue fever to the Ebola virus, have raised concern within the medical and scientific communities. Officials from the U.S. Department of Health and Human Services and the Centers for Disease Control and Prevention said they were not even aware of the policies until contacted by The Associated Press ... and privately expressed alarm. They make "no scientific sense," said Peter Palese, chairman of the microbiology department at Mount Sinai School of Medicine in New York. Some experts say the idea of using vaccines for bioweapons is far-fetched.

New federally financed drug research reveals a stark disparity: children covered by Medicaid are given powerful antipsychotic medicines at a rate four times higher than children whose parents have private insurance. And the Medicaid children are more likely to receive the drugs for less severe conditions than their middle-class counterparts, the data shows. Those findings, by a team from Rutgers and Columbia, are almost certain to add fuel to a long-running debate. Do too many children from poor families receive powerful psychiatric drugs not because they actually need them – but because it is deemed the most efficient and cost-effective way to control problems that may be handled much differently for middle-class children? The questions go beyond the psychological impact on Medicaid children, serious as that may be. Antipsychotic drugs can also have severe physical side effects, causing drastic weight gain and metabolic changes resulting in lifelong physical problems. Part of the reason is insurance reimbursements, as Medicaid often pays much less for counseling and therapy than private insurers do. Studies have found that children in low-income families may have a higher rate of mental health problems – perhaps two to one – compared with children in better-off families. But that still does not explain the four-to-one disparity in prescribing antipsychotics.

Note: For many important health reports from reliable sources, click here.

Suzanne Somers is at it again. She's back with a new book [on an] emotional topic: Cancer treatment. Specifically, she argues against what she sees as the vast and often pointless use of chemotherapy. Somers, who has rejected chemo herself, seems to relish the fight. "Cancer's an epidemic," said the 63-year-old actress ... a day before [the] release of Knockout: Interviews with Doctors Who Are Curing Cancer--And How to Prevent Getting It in the First Place, her 19th book. "And yet we keep going back to the same old pot, because it's all we've got. Well, this is a book about options." Though she may be one of the most visible, Somers is hardly the only celebrity who's advocated alternative treatments recently. The late Farrah Fawcett underwent a mix of traditional and alternative treatments, and made a poignant plea for supporting alternative methods in her film, "Farrah's Story." Actress Jenny McCarthy advocates a special dietary regime, supplements, metal detox and delayed vaccines to treat autism. In fact, Somers does view chemotherapy as effective for some cancers, but not for the most common, including lung and breast cancer. Diagnosed with breast cancer a decade ago, she had a lumpectomy and radiation, but declined chemotherapy, as she did more recently when briefly misdiagnosed with pervasive cancer.

Note: To watch a video clip of this, click here. For her harrowing experience of being misdiagnosed with stage four cancer, click here. And if you want to understand how big money sometimes ruthlessly acts to stop cancer cures, click here. For media articles discussing potentially powerful cancer cures and how industry sometimes will not support them, click here.

CT [Computed Tomography] scans deliver far more radiation than has been believed and may contribute to 29,000 new cancers each year, along with 14,500 deaths, suggest two studies in today's Archives of Internal Medicine. One study, led by the National Cancer Institute's Amy Berrington de Gonzalez, used existing exposure data to estimate how many cancers might be caused by CT scans. Another study in the journal suggests the problem may even be worse. In that study, researchers found that people may be exposed to up to four times as much radiation as estimated by earlier studies. While previous studies relied on dummies equipped with sensors, authors of the new paper studied 1,119 patients at four San Francisco-area hospitals. Based on those higher measurements, a patient could get as much radiation from one CT scan as 74 mammograms or 442 chest X-rays. Young people are at highest risk from excess radiation, partly because they have many years ahead of them in which cancers could develop. Among 20-year-old women who get one coronary angiogram, a CT scan of the heart, one in 150 will develop cancer related to the procedure.

Note: For many important health reports from reliable sources, click here.

This country hasn't used land mines in nearly 20 years. It no longer makes the indiscriminate killers nor provides them to allies. Why then is President Obama - off to Oslo this week to collect a Nobel Peace Prize - refusing to sign an international treaty to ban the shrapnel-spewing buried bombs? His refusal is ... shameful. The devices, which maim and kill for years after a conflict ends, caused more than 5,000 casualties last year in the world's poorest places such as Cambodia, Angola and Central America. Obama's stance puts him in line with Presidents George W. Bush and Bill Clinton, who both ducked a chance to put this country in line with more than 150 nations that have signed the treaty. Other notable non-signers: China, Russia, India, Pakistan and Cuba. Is this the company we want to keep? Sticking with land mines is a puzzler. The United States has a reported stockpile of 10 million devices, though it hasn't deployed any since the 1991 Gulf War. By signing the agreement, the Pentagon would hardly be giving up a mainstay weapon. It's time for Obama to go in a new direction. He should sign, not equivocate, on a treaty that Washington has avoided for over a decade. Here's a thought while typing up your Peace Prize acceptance speech, Mr. President: It's time to ban land mines.

Note: The refusal to sign the worldwide landmine ban treaty seems to be a puzzler, until you realize the US government is protecting the rights to profit of US arms corporations. For a retired Marine general's analysis of the profiteering that is the principal purpose for war, "War is a Racket,"click here.

This is the 25th anniversary of the Bhopal gas disaster. [It] started one night when a pesticide plant owned by the American chemical giant Union Carbide leaked a cloud of poisonous gas. Before the sun rose, almost 4,000 human beings capable of love and anguish sank to their knees and did not get up. Half a million more fell ill, many with severely damaged lungs and eyes. An additional 15,000 people have since died from the aftereffects, and 10 to 30 people are said to die every month from exposure to the hundreds of tons of toxic waste left over in the former factory. But amazingly, the site still has not been cleaned up, because Dow Chemical, which since acquired Union Carbide, refuses to accept any responsibility. In 2001, the maker of napalm married the bane of Bhopal: Dow Chemical bought Union Carbide for $11.6 billion and promptly distanced itself from the disaster. Union Carbide and Dow were allowed to get away with it because of the international legal structures that protect multinationals from liability. Union Carbide sold its Indian subsidiary and pulled out of India. Warren Anderson, the Union Carbide chief executive at the time of the gas leak, lives in luxurious exile in the Hamptons, even though there’s an international arrest warrant out for him for culpable homicide. The Indian government has yet to pursue an extradition request. Imagine if an Indian chief executive had jumped bail for causing an industrial disaster that killed tens of thousands of Americans. What are the chances he’d be sunning himself in Goa?

Note: For lots more from reliable sources on corporate corruption, click here.

A $112 million settlement involving alleged drug kickbacks that the Justice Dept. announced with the nation's largest nursing home pharmacy and a generic drug manufacturer on Nov. 3 is part of a wide-ranging investigation of suspected Medicaid fraud by the pharmaceutical industry. Critics say the continuing probe, which involves ... major drugmakers, highlights what they describe as an industry practice of paying money to outfits that provide drugs to consumers, in return for preferential treatment. Because those alleged payoffs have the effect of compromising patient care and driving up costs for government and private health insurers, cases like the settlement unsealed with Omnicare (OCR) in Covington, Ky., and IVAX Pharmaceuticals in Weston, Fla., could bolster opposition to the controversial deal the Obama Administration reached with the pharmaceutical industry to win its support for health-reform legislation. Many Democrats say the Administration should have asked for much bigger cost savings from drugmakers. Patrick Burns, a spokesman for Taxpayers Against Fraud, a nonprofit Washington group that promotes whistleblower suits, says the Justice Dept. is backed up with pharmaceutical fraud cases. Since drugmakers offer so many similar products, he contends, they rely on kickbacks to give their products a market edge. "In the pharmaceutical industry, the business isn't selling the best drug, it's the best scheme of kickbacks to the prescriber."

Note: For lots more from reliable sources on corporate corruption, click here.

With food stamp use at record highs and climbing every month, a program once scorned as a failed welfare scheme now helps feed one in eight Americans and one in four children. It has grown so rapidly in places so diverse that it is becoming nearly as ordinary as the groceries it buys. More than 36 million people use inconspicuous plastic cards for staples like milk, bread and cheese, swiping them at counters in blighted cities and in suburbs pocked with foreclosure signs. Virtually all have incomes near or below the federal poverty line, but their eclectic ranks testify to the range of people struggling with basic needs. They include single mothers and married couples, the newly jobless and the chronically poor, longtime recipients of welfare checks and workers whose reduced hours or slender wages leave pantries bare. There are 239 counties in the United States where at least a quarter of the population receives food stamps, according to an analysis of local data collected by The New York Times. In more than 750 counties, the program helps feed one in three blacks. In more than 800 counties, it helps feed one in three children. In the Mississippi River cities of St. Louis, Memphis and New Orleans, half of the children or more receive food stamps. Even in Peoria, Ill. — Everytown, U.S.A. — nearly 40 percent of children receive aid. While use is greatest where poverty runs deep, the growth has been especially swift in once-prosperous places hit by the housing bust.

Note: For more from reliable sources on the impacts and realities of the Wall Street financial crisis, click here.

Critics point to Canada and Britain as the poster children of what could happen here with a "government takeover" of health coverage. But three other wealthy nations - the Netherlands, Switzerland and Germany - offer much closer parallels, as well as lessons. Health care systems in the three nations more closely resemble the U.S. system of insurance-based coverage. Holland and Switzerland rely exclusively on private insurance, and all three rely on private doctors. The three European nations deliver universal coverage and world-class quality at a fraction of what Americans spend. All of them require that everyone purchase insurance, make sure everyone can afford it and ban insurers from such practices as refusing to cover the sick that are common in the United States. European health care is universal, but contrary to popular perception, it is not all nationalized. Most of Europe spends about 10 percent of its national income on health care and covers everyone. The United States will spend 18 percent this year and leave 47 million people uninsured. Europe has more doctors, more hospital beds and more patient visits than the United States. Take Switzerland: 4.9 doctors per thousand residents compared with 2.4 in the United States. And cost? The average cost for a hospital stay is $9,398 in relatively high-cost Switzerland and $17,206 in the United States.

Note: Maybe it boils down to whether we want our health controlled more by profit motive or by government bureaucracies One thing is for sure, the average U.S. citizen is getting much less for a greater cost than those in other developed countries.

Drug company GlaxoSmithKline has told Canadian doctors to stop using one lot of its H1N1 vaccine until an investigation into a higher-than-expected number of severe allergic reactions is completed. The U.S. vaccine will not be identical to Arepanrix, the GSK H1N1 vaccine used in Canada. Arepanrix contains an adjuvant, a substance designed to boost the immune response, but adjuvants have never been approved for use in U.S. flu vaccines. Almost all of the 172,000 doses in question, distributed the week of Nov. 2 to six Canadian provinces, already have been administered, said Geoffrey Matthews, a spokeswoman for the Public Health Agency of Canada, which, with GSK and Health Canada, is investigating cases of anaphylaxis. Symptoms of anaphylaxis include trouble breathing, chest tightness and swelling of the mouth and throat. Six cases have been reported, Matthews says. In the USA, the Vaccine Adverse Event Reporting System said that as of Nov. 13 it had received 116 reports of serious health events related to the vaccine, including eight deaths – similar to the number in previous years after a similar number of seasonal flu vaccine doses had been shipped.

Note: For lots more on the risks of swine flu vaccines, click here.

As the pandemic H1N1 influenza surges with the onset of winter, the nations of Eastern Europe and the former Soviet Union appear particularly vulnerable to the deadly virus. Burdened with weak health-care systems, relatively inexperienced news media outlets and shaky governments that have little public trust, the region also seems ripe for panic and political strife over the flu. The potential for trouble is already on display in Ukraine, where 1.5 million of its 46 million people have had diagnoses of flu and respiratory illnesses since the start of the outbreak and 356 have died, according to the government. More telling than the numbers, however, has been the widespread fear the virus has caused in Ukraine, and the outsize impact it has had on the nation's political landscape. Anxious residents have overwhelmed hospitals and pharmacies, buying up supplies of medicine, gauze masks and home remedies such as lemons and garlic. Rumors have proliferated that people are dying of a new, more lethal strain of the virus. Semyon Gluzman, a psychiatrist and Soviet-era dissident in Kiev, said the fear was a rational response in a nation with a dysfunctional health-care system and a corrupt, ineffective government. "What we're seeing is a normal, psychological reaction to the complete incompetence of the state authorities," he said. "People are scared, and they don't know who to trust anymore."

France's highest court has ruled that US agrochemical giant Monsanto had not told the truth about the safety of its best-selling weed-killer, Roundup. The court confirmed an earlier judgment that Monsanto had falsely advertised its herbicide as "biodegradable" and claimed it "left the soil clean". The company was fined 15,000 euros (Ł13,800; $22,400). Roundup is the world's best-selling herbicide. Monsanto also sells crops genetically-engineered to be tolerant to Roundup. French environmental groups had brought the case in 2001 on the basis that glyphosate, Roundup's main ingredient, is classed as "dangerous for the environment" by the European Union. Earlier this month, Monsanto reported a fourth quarter loss of $233m (Ł147m), driven mostly by a drop in sales of its Roundup brand.

Note: For an article on the dangers of Monsanto's RoundUp, click here.

Even as drug makers promise to support Washington's health care overhaul by shaving $8 billion a year off the nation's drug costs after the legislation takes effect, the industry has been raising its prices at the fastest rate in years. In the last year, the industry has raised the wholesale prices of brand-name prescription drugs by about 9 percent, according to industry analysts. That will add more than $10 billion to the nation's drug bill, which is on track to exceed $300 billion this year. By at least one analysis, it is the highest annual rate of inflation for drug prices since 1992. The drug trend is distinctly at odds with the direction of the Consumer Price Index, which has fallen by 1.3 percent in the last year. Critics say the industry is trying to establish a higher price base before Congress passes legislation that tries to curb drug spending in coming years. "When we have major legislation anticipated, we see a run-up in price increases," says Stephen W. Schondelmeyer, a professor of pharmaceutical economics at the University of Minnesota. A Harvard health economist, Joseph P. Newhouse, said he found a similar pattern of unusual price increases after Congress added drug benefits to Medicare a few years ago, giving tens of millions of older Americans federally subsidized drug insurance. Just as the program was taking effect in 2006, the drug industry raised prices by the widest margin in a half-dozen years. "They try to maximize their profits," Mr. Newhouse said.

Note: For lots more from reliable sources on corporate corruption, click here.

In the official record of the historic House debate on overhauling health care, the speeches of many lawmakers echo with similarities. Often, that was no accident. Statements by more than a dozen lawmakers were ghostwritten, in whole or in part, by Washington lobbyists working for Genentech, one of the world's largest biotechnology companies. E-mail messages obtained by The New York Times show that the lobbyists drafted one statement for Democrats and another for Republicans. The lobbyists ... were remarkably successful in getting the statements printed in the Congressional Record under the names of different members of Congress. Genentech, a subsidiary of the Swiss drug giant Roche, estimates that 42 House members picked up some of its talking points – 22 Republicans and 20 Democrats, an unusual bipartisan coup for lobbyists. In an interview, Representative Bill Pascrell Jr., Democrat of New Jersey, said: "I regret that the language was the same. I did not know it was." He said he got his statement from his staff and "did not know where they got the information from." In recent years, Genentech's political action committee and lobbyists for Roche and Genentech have made campaign contributions to many House members. And company employees have been among the hosts at fund-raisers for some of those lawmakers.

Note: For revealing reports from major media sources on government corruption, click here.

European scientists and health authorities are facing angry questions about why H1N1 flu has not caused death and destruction on the scale first feared, and they need to respond deftly to ensure public support. Accusations are flying in British and French media that the pandemic has been "hyped" by medical researchers to further their own cause, boost research grants and line the pockets of drug companies. Britain's Independent newspaper this week asked "Pandemic? What Pandemic?." France's Le Parisien newspaper ran the headline: "Swine flu: why the French distrust the vaccine" and noted a gap between the predicted impact of H1N1 and the less dramatic reality. "Dangerous liaisons between certain experts, the labs and the government, the obscurity of the contracts between the state and the pharma firms have added to the doubt." In Britain, health authorities' original worst-case scenario -- which said as many as 65,000 could die from H1N1 -- has twice been revised down and the prediction is now for around 1,000 deaths, way below the average annual toll of 4,000 to 8,000 deaths from seasonal winter flu.

Note: It's quite interesting and telling that a thorough Internet seach showed that no major media picked up this article from Reuters News Agency

Although federal health officials decline to use the word "peaked," the current wave of swine flu appears to have done so in the United States. Flu activity is coming down in all regions of the country, the Centers for Disease Control and Prevention said Friday, though it is still rising in Hawaii, Maine and some isolated areas. The World Health Organization said Friday that there were "early signs of a peak" in much of the United States. On Wednesday, the American College Health Association, which surveys over 250 colleges with more than three million students, said new cases of flu had dropped in the week ending Nov. 13. It was the first drop since school resumed in the fall, and it was significant – new cases were down 27 percent from the week before. And on Friday, Quest Diagnostics, the country's largest laboratory, said its tests of 142,000 suspected flu specimens since May showed that the flu peaked in late October. Nonetheless, Dr. Anne Schuchat, the director of immunization and respiratory diseases at the C.D.C., chose her words carefully, saying: "I wish I knew if we had hit the peak. Even if a peak has occurred, half the people who are going to get sick haven't gotten sick yet." The drop was clearly not caused by the swine flu vaccine drive, which has not gone as fast as the authorities had hoped.

Note: Just like the avian flu scare a few years ago, the swine flu hype has turned out to be largely a whimper, yet the pharmaceutical companies are happy, as again they have made billions of dollars from the massive amonts of vaccines and drugs purchased by the government with your tax dollars. For more, click here and here.

For the first time in 20 years, a government panel is telling women in their [forties] to stop getting routine mammograms and recommending that a host of other breast cancer screenings slow down. The United States Preventive Service Task Force announced ... that it recommends against annual mammograms for women age 40 to 49 because, they say, the benefits of testing do not outweigh the "harms" and risks. USPSTF still recommends doctors start screening all women over age 50, but with a mammogram once every two years instead of annually. The task force also ... said evidence was insufficient to recommend mammograms for women older than 74. The recommendations announced today, which contradict the American Cancer Society, have already pitted doctors, women, insurers and radiology groups in a fierce debate about who should get a mammogram and when. Many patient advocates wonder if money fueled the decision. However, Dr. Diana Petitti, vice chair of USPSTF, said the task force never looked at costs in their research or their recommendations. Instead, the task force reviewed a number of studies to compile the benefits of mammograms, such as how many cancers were detected and how many lives were saved, and the harms of mammograms, such as how many false positives popped up, how many unnecessary tests were done and how much extra radiation women were exposed to during the false positive testing.

Note: For a powerful article compiling important information and key quotes of doctors and researchers revealing the dangers of mammograms, click here.

Important Note: Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.